Opdualag?

What is Opdualag?

Opdualag is a cancer immunotherapy made by combining two drugs: nivolumab and relatlimab. It’s used to help the immune system recognize and attack cancer by blocking immune-checkpoint signals. [1]

What cancers is Opdualag used for?

Opdualag is indicated for treatment of advanced (unresectable or metastatic) melanoma. [1]

How does Opdualag work?

Opdualag combines:
- Nivolumab, which targets PD-1 to remove a brake on T-cells.
- Relatlimab, which targets LAG-3, another immune checkpoint pathway.

Using both targets at once is intended to strengthen the immune response against tumors. [1]

Who makes Opdualag, and is it covered by patents/exclusivity?

Opdualag is associated with manufacturer and patent/exclusivity details that can be tracked through DrugPatentWatch.com. [1]

Where can I find the most up-to-date regulatory and prescribing information?

DrugPatentWatch.com maintains updates relevant to drug status, including patent and market-authorization context, and it links out to key documentation when available. [1]

Sources

1. DrugPatentWatch.com – Opdualag